Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)

Trial Profile

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary) ; Dalteparin sodium; Enoxaparin sodium; Fondaparinux sodium; Warfarin
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms CANVAS
  • Most Recent Events

    • 06 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 02 Oct 2016 Planned initiation date changed from 1 Jun 2016 to 1 Oct 2016.
    • 31 May 2016 Treatment arms changed from 4 to 3.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top